Safety, Tolerability and Pharmacokinetics of FTX-6058

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Adult Subjects, Sickle Cell Disease

In brief

This is a study to evaluate the safety, tolerability and pharmacokinetics of FTX-6058 in healthy adult subjects and adult subjects with sickle cell disease (SCD).

Key facts

Study ID

NCT04586985

Run by

Fulcrum Therapeutics

People needed

109

Starts

2020-10-26

Expected to finish

2022-11-15

Last updated by the study team

2022-12-12

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

Where it is running

• Atlanta Center for Medical Research - Sickle Cell Subjects Only — Atlanta, Georgia, United States
• Altasciences Clinical Kansas, Inc. - Healthy Adults Subjects Only — Overland Park, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.